Gene expression profiling identifies inflammation and angiogenesis as distinguishing features of canine hemangiosarcoma

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Tamburini, Beth A ^a   Phang, Tzu L ^b,c   Fosmire, Susan P ^a,b   Scott, Milcah C ^d,e   Trapp, Susan C ^b,h   Duckett, Megan M ^d,e   Robinson, Sally R ^d,e   Slansky, Jill E ^a,c   Sharkey, Leslie C ^d,e   Cutter, Gary R ^f   Wojcieszyn, John W ^g   Bellgrau, Donald ^a,c   Gemmill, Robert M ^b,c,i   Hunter, Lawrence E ^c,d   Modiano, Jaime F ^a,c,d,e  

^a UNIVERSITY OF COLORADO   (United States)

^b UCD   (United States)

^c UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

^e UNIVERSITY OF MINNESOTA   (United States)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^g IHC Services   (United States)

^h Array Bio Pharma Inc   (United States)

ⁱ MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TISSUE INHIBITOR OF METALLOPROTEINASE 1; VON HIPPEL LINDAU PROTEIN; RAS PROTEIN;

ANGIOSARCOMA; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BIOINFORMATICS; CANCER INVASION; CARCINOGENESIS; CELL ADHESION; CELL CYCLE; CELL PROLIFERATION; CELL STRUCTURE; CODON; CONTROLLED STUDY; DNA SEQUENCE; DOG; DOWN REGULATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENE MUTATION; GENETIC SCREENING; IMMUNOHISTOCHEMISTRY; INFLAMMATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RNA SEQUENCE; SIGNAL TRANSDUCTION; UPREGULATION; VALIDATION PROCESS; ANIMAL; ANIMAL DISEASE; DNA MICROARRAY; FEMALE; GENETICS; HUMAN; MALE; METABOLISM; MUTATION; NEOVASCULARIZATION (PATHOLOGY); TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; DOGS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HEMANGIOSARCOMA; HUMANS; INFLAMMATION; MALE; MUTATION; NEOVASCULARIZATION, PATHOLOGIC; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RAS PROTEINS; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 78049516078     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-619     Document Type: Article

References (71)

1. Koch M, Nielsen GP, Yoon SS. Malignant tumors of blood vessels: angiosarcomas, hemangioendotheliomas, and hemangioperictyomas. J Surg Oncol 2008, 97(4):321-329. 10.1002/jso.20973, 18286475.
2. Cohen SM, Storer RD, Criswell KA, Doerrer NG, Dellarco VL, Pegg DG, Wojcinski ZW, Malarkey DE, Jacobs AC, Klaunig JE, et al. Hemangiosarcoma in rodents: mode-of-action evaluation and human relevance. Toxicol Sci 2009, 111(1):4-18. 10.1093/toxsci/kfp131, 19525443.
3. Skubitz KM, D'Adamo DR. Sarcoma. Mayo Clin Proc 2007, 82(11):1409-1432. 10.4065/82.11.1409, 17976362.
4. Vail DM, MacEwen EG. Spontaneously occurring tumors of companion animals as models for human cancer. Cancer Invest 2000, 18(8):781-792. 10.3109/07357900009012210, 11107448.
5. Clifford CA, Hughes D, Beal MW, Mackin AJ, Henry CJ, Shofer FS, Sorenmo KU. Plasma vascular endothelial growth factor concentrations in healthy dogs and dogs with hemangiosarcoma. J Vet Intern Med 2001, 15(2):131-135. 10.1111/j.1939-1676.2001.tb01244.x, 11300596.
6. Hammond TN, Pesillo-Crosby SA. Prevalence of hemangiosarcoma in anemic dogs with a splenic mass and hemoperitoneum requiring a transfusion: 71 cases (2003-2005). J Am Vet Med Assoc 2008, 232(4):553-558. 10.2460/javma.232.4.553, 18279091.
7. Hillers KR, Lana SE, Fuller CR, LaRue SM. Effects of palliative radiation therapy on nonsplenic hemangiosarcoma in dogs. J Am Anim Hosp Assoc 2007, 43(4):187-192.
8. Vail DM, MacEwen EG, Kurzman ID, Dubielzig RR, Helfand SC, Kisseberth WC, London CA, Obradovich JE, Madewell BR, Rodriguez CO, et al. Liposome-encapsulated muramyl tripeptide phosphatidylethanolamine adjuvant immunotherapy for splenic hemangiosarcoma in the dog: a randomized multi-institutional clinical trial. Clin Cancer Res 1995, 1(10):1165-1170.
9. Cohen LA, Powers B, Amin S, Desai D. Treatment of canine haemangiosarcoma with suberoylanilide hydroxamic acid, a histone deacetylase inhibitor. Vet Comp Oncol 2004, 2(4):243-248. 10.1111/j.1476-5810.2004.00057.x, 19379298.
10. Antiangiogenic therapy for canine cancers. , http://www.angio.org/pets_and_wildlife/pet/canine_cancer/therapy.html
11. U'Ren LW, Biller BJ, Elmslie RE, Thamm DH, Dow SW. Evaluation of a novel tumor vaccine in dogs with hemangiosarcoma. J Vet Intern Med 2007, 21(1):113-120. 10.1111/j.1939-1676.2007.tb02936.x, 17338158.
12. Lana S, U'Ren L, Plaza S, Elmslie R, Gustafson D, Morley P, Dow S. Continuous low-dose oral chemotherapy for adjuvant therapy of splenic hemangiosarcoma in dogs. J Vet Intern Med 2007, 21(4):764-769. 10.1111/j.1939-1676.2007.tb03019.x, 17708397.
13. Rusk A, McKeegan E, Haviv F, Majest S, Henkin J, Khanna C. Preclinical evaluation of antiangiogenic thrombospondin-1 peptide mimetics, ABT-526 and ABT-510, in companion dogs with naturally occurring cancers. Clin Cancer Res 2006, 12(24):7444-7455. 10.1158/1078-0432.CCR-06-0109, 17189418.
14. Helfand SC. Canine hemangiosarcoma: a tumor of contemporary interest. Cancer Ther 2008, 6:457-462.
15. Wu Y, Zhou BP. Inflammation: a driving force speeds cancer metastasis. Cell Cycle 2009, 8(20):3267-3273. 10.4161/cc.8.20.9699, 19770594.
16. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008, 454(7203):436-444. 10.1038/nature07205, 18650914.
17. Lin WW, Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 2007, 117(5):1175-1183. 10.1172/JCI31537, 1857251, 17476347.
18. Fosmire SP, Dickerson EB, Scott AM, Bianco SR, Pettengill MJ, Meylemans H, Padilla M, Frazer-Abel AA, Akhtar N, Getzy DM, et al. Canine malignant hemangiosarcoma as a model of primitive angiogenic endothelium. Lab Invest 2004, 84(5):562-572. 10.1038/labinvest.3700080, 15064773.
19. Akhtar N, Padilla M, Dickerson E, Steinberg H, Breen M, Auerbach R, Helfand S. Interleukin-12 inhibits tumor growth in a novel angiogenesis canine hemangiosarcoma xenograft model. Neoplasia 2004, 6(2):106-116. 10.1593/neo.03334, 1502086, 15140399.
20. Pettersson A, Nagy JA, Brown LF, Sundberg C, Morgan E, Jungles S, Carter R, Krieger JE, Manseau EJ, Harvey VS, et al. Heterogeneity of the angiogenic response induced in different normal adult tissues by vascular permeability factor/vascular endothelial growth factor. Lab Invest 2000, 80(1):99-115. 10.1038/labinvest.3780013, 10653008.
21. Thamm DH, Dickerson EB, Akhtar N, Lewis R, Auerbach R, Helfand SC, MacEwen EG. Biological and molecular characterization of a canine hemangiosarcoma-derived cell line. Res Vet Sci 2006, 81(1):76-86. 10.1016/j.rvsc.2005.09.005, 16256156.
22. Hirsch E, Ciraolo E, Ghigo A, Costa C. Taming the PI3K team to hold inflammation and cancer at bay. Pharmacol Ther 2008, 118(2):192-205. 10.1016/j.pharmthera.2008.02.004, 18420279.
23. Dickerson EB, Thomas R, Fosmire SP, Lamerato-Kozicki AR, Bianco SR, Wojcieszyn JW, Breen M, Helfand SC, Modiano JF. Mutations of phosphatase and tensin homolog deleted from chromosome 10 in canine hemangiosarcoma. Vet Pathol 2005, 42(5):618-632. 10.1354/vp.42-5-618, 16145208.
24. Wang X, Shi Y, Wang J, Huang G, Jiang X. Crucial role of the C-terminus of PTEN in antagonizing NEDD4-1-mediated PTEN ubiquitination and degradation. Biochem J 2008, 414(2):221-229. 10.1042/BJ20080674, 18498243.
25. Leslie NR, Yang X, Downes CP, Weijer CJ. PtdIns(3,4,5)P(3)-dependent and -independent roles for PTEN in the control of cell migration. Curr Biol 2007, 17(2):115-125. 10.1016/j.cub.2006.12.026, 1885949, 17240336.
26. Okumura K, Zhao M, Depinho RA, Furnari FB, Cavenee WK. Cellular transformation by the MSP58 oncogene is inhibited by its physical interaction with the PTEN tumor suppressor. Proc Natl Acad Sci USA 2005, 102(8):2703-2706. 10.1073/pnas.0409370102, 549467, 15659546.
27. Tate G, Suzuki T, Mitsuya T. Mutation of the PTEN gene in a human hepatic angiosarcoma. Cancer Genet Cytogenet 2007, 178(2):160-162. 10.1016/j.cancergencyto.2007.07.017, 17954274.
28. Saito T, Barbin A, Omori Y, Yamasaki H. Connexin 37 mutations in rat hepatic angiosarcomas induced by vinyl chloride. Cancer Res 1997, 57(3):375-377.
29. Marion MJ, Boivin-Angele S. Vinyl chloride-specific mutations in humans and animals. IARC Sci Publ 1999, (150):315-324.
30. Froment O, Boivin S, Barbin A, Bancel B, Trepo C, Marion MJ. Mutagenesis of ras proto-oncogenes in rat liver tumors induced by vinyl chloride. Cancer Res 1994, 54(20):5340-5345.
31. Hong HL, Ton TV, Devereux TR, Moomaw C, Clayton N, Chan P, Dunnick JK, Sills RC. Chemical-specific alterations in ras, p53, and beta-catenin genes in hemangiosarcomas from B6C3F1 mice exposed to o-nitrotoluene or riddelliine for 2 years. Toxicol Appl Pharmacol 2003, 191(3):227-234. 10.1016/S0041-008X(03)00165-0, 13678655.
32. Weihrauch M, Bader M, Lehnert G, Koch B, Wittekind C, Wrbitzky R, Tannapfel A. Mutation analysis of K-ras-2 in liver angiosarcoma and adjacent nonneoplastic liver tissue from patients occupationally exposed to vinyl chloride. Environ Mol Mutagen 2002, 40(1):36-40. 10.1002/em.10084, 12211074.
33. Duddy SK, Gorospe SM, Bleavins MR, de la Iglesia FA. Spontaneous and thiazolidinedione-induced B6C3F1 mouse hemangiosarcomas exhibit low ras oncogene mutation frequencies. Toxicol Appl Pharmacol 1999, 160(2):133-140. 10.1006/taap.1999.8763, 10527912.
34. Sherr CJ. Principles of tumor suppression. Cell 2004, 116(2):235-246. 10.1016/S0092-8674(03)01075-4, 14744434.
35. Stockmann C, Doedens A, Weidemann A, Zhang N, Takeda N, Greenberg JI, Cheresh DA, Johnson RS. Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis. Nature 2008, 456(7223):814-818. 10.1038/nature07445, 18997773.
36. Lamerato-Kozicki AR, Helm KM, Jubala CM, Cutter GR, Modiano JF. Canine hemangiosarcoma originates from hematopoietic precursors with potential for endothelial differentiation. Exp Hematol 2006, 34(7):870-878. 10.1016/j.exphem.2006.04.013, 16797414.
37. Yoder MC, Mead LE, Prater D, Krier TR, Mroueh KN, Li F, Krasich R, Temm CJ, Prchal JT, Ingram DA. Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. Blood 2007, 109(5):1801-1809. 10.1182/blood-2006-08-043471, 1801067, 17053059.
38. Spangler WL, Culbertson MR. Prevalence, type, and importance of splenic diseases in dogs: 1,480 cases (1985-1989). J Am Vet Med Assoc 1992, 200(6):829-834.
39. Thomas R, Scott A, Langford CF, Fosmire SP, Jubala CM, Lorentzen TD, Hitte C, Karlsson EK, Kirkness E, Ostrander EA, et al. Construction of a 2-Mb resolution BAC microarray for CGH analysis of canine tumors. Genome Res 2005, 15(12):1831-1837. 10.1101/gr.3825705, 1356122, 16339382.
40. Tamburini BA, Trapp S, Phang TL, Schappa JT, Hunter LE, Modiano JF. Gene expression profiles of sporadic canine hemangiosarcoma are uniquely associated with breed. PLoS ONE 2009, 4(5):e5549.. 10.1371/journal.pone.0005549, 2680013, 19461996.
41. Watzinger F, Mayr B, Haring E, Lion T. High sequence similarity within ras exons 1 and 2 in different mammalian species and phylogenetic divergence of the ras gene family. Mamm Genome 1998, 9(3):214-219. 10.1007/s003359900728, 9501305.
42. Page GP, Edwards JW, Gadbury GL, Yelisetti P, Wang J, Trivedi P, Allison DB. The PowerAtlas: a power and sample size atlas for microarray experimental design and research. BMC Bioinformatics 2006, 7:84. 10.1186/1471-2105-7-84, 1395338, 16504070.
43. Koenig A, Bianco SR, Fosmire S, Wojcieszyn J, Modiano JF. Expression and significance of p53, Rb, p21/waf-1, p16/ink-4a, and PTEN tumor suppressors in canine melanoma. Vet Pathol 2002, 39(4):458-472. 10.1354/vp.39-4-458, 12126149.
44. Chirco R, Liu XW, Jung KK, Kim HR. Novel functions of TIMPs in cell signaling. Cancer Metastasis Rev 2006, 25(1):99-113. 10.1007/s10555-006-7893-x, 16680576.
45. Reid A, Gould A, Brand N, Cook M, Strutt P, Li J, Licht J, Waxman S, Krumlauf R, Zelent A. Leukemia translocation gene, PLZF, is expressed with a speckled nuclear pattern in early hematopoietic progenitors. Blood 1995, 86(12):4544-4552.
46. Larsen M, Artym VV, Green JA, Yamada KM. The matrix reorganized: extracellular matrix remodeling and integrin signaling. Curr Opin Cell Biol 2006, 18(5):463-471. 10.1016/j.ceb.2006.08.009, 16919434.
47. Yamini B, VanDenBrink PL, Refsal KR. Ovarian steroid cell tumor resembling luteoma associated with hyperadrenocorticism (Cushing's disease) in a dog. Vet Pathol 1997, 34(1):57-60. 10.1177/030098589703400112, 9150550.
48. Modiano JF, Breen M, Burnett RC, Parker HG, Inusah S, Thomas R, Avery PR, Lindblad-Toh K, Ostrander EA, Cutter GC, et al. Distinct B-cell and T-cell lymphoproliferative disease prevalence among dog breeds indicates heritable risk. Cancer Res 2005, 65(13):5654-5661. 10.1158/0008-5472.CAN-04-4613, 15994938.
49. Miettinen M. From morphological to molecular diagnosis of soft tissue tumors. Adv Exp Med Biol 2006, 587:99-113. full_text, 17163160.
50. Ackermann M. Pathogenesis of gammaherpesvirus infections. Vet Microbiol 2006, 113(3-4):211-222. 10.1016/j.vetmic.2005.11.008, 16332416.
51. Rose TM. CODEHOP-mediated PCR - a powerful technique for the identification and characterization of viral genomes. Virol J 2005, 2:20. 10.1186/1743-422X-2-20, 1079958, 15769292.
52. Pressler BM, Williams LE, Ramos-Vara JA, Anderson KI. Sequencing of the von Hippel-Lindau gene in canine renal carcinoma. J Vet Intern Med 2009, 23(3):592-597. 10.1111/j.1939-1676.2009.0310.x, 19422471.
53. Lin PY, Fosmire SP, Park SH, Park JY, Baksh S, Modiano JF, Weiss RH. Attenuation of PTEN increases p21 stability and cytosolic localization in kidney cancer cells: a potential mechanism of apoptosis resistance. Mol Cancer 2007, 6:16. 10.1186/1476-4598-6-16, 1803787, 17300726.
54. Mense SM, Sengupta A, Zhou M, Lan C, Bentsman G, Volsky DJ, Zhang L. Gene expression profiling reveals the profound upregulation of hypoxia-responsive genes in primary human astrocytes. Physiol Genomics 2006, 25(3):435-449. 10.1152/physiolgenomics.00315.2005, 16507782.
55. Harris AL. Hypoxia--a key regulatory factor in tumour growth. Nat Rev Cancer 2002, 2(1):38-47. 10.1038/nrc704, 11902584.
56. Antonescu CR, Yoshida A, Guo T, Chang NE, Zhang L, Agaram NP, Qin LX, Brennan MF, Singer S, Maki RG. KDR activating mutations in human angiosarcomas are sensitive to specific kinase inhibitors. Cancer Res 2009, 69(18):7175-7179. 10.1158/0008-5472.CAN-09-2068, 2763376, 19723655.
57. Chiaretti S, Li X, Gentleman R, Vitale A, Vignetti M, Mandelli F, Ritz J, Foa R. Gene expression profile of adult T-cell acute lymphocytic leukemia identifies distinct subsets of patients with different response to therapy and survival. Blood 2004, 103(7):2771-2778. 10.1182/blood-2003-09-3243, 14684422.
58. Lindstedt M, Johansson-Lindbom B, Borrebaeck CA. Global reprogramming of dendritic cells in response to a concerted action of inflammatory mediators. Int Immunol 2002, 14(10):1203-1213. 10.1093/intimm/dxf082, 12356685.
59. Theilgaard-Monch K, Knudsen S, Follin P, Borregaard N. The transcriptional activation program of human neutrophils in skin lesions supports their important role in wound healing. J Immunol 2004, 172(12):7684-7693.
60. Brentani H, Caballero OL, Camargo AA, da Silva AM, da Silva WA, Dias Neto E, Grivet M, Gruber A, Guimaraes PE, Hide W, et al. The generation and utilization of a cancer-oriented representation of the human transcriptome by using expressed sequence tags. Proc Natl Acad Sci USA 2003, 100(23):13418-13423. 10.1073/pnas.1233632100, 263829, 14593198.
61. Chan B, Sukhatme VP. Suppression of Tie-1 in endothelial cells in vitro induces a change in the genome-wide expression profile reflecting an inflammatory function. FEBS Lett 2009, 583(6):1023-1028. 10.1016/j.febslet.2009.02.027, 2666009, 19236867.
62. Heller DA, Clifford CA, Goldschmidt MH, Holt DE, Manfredi MJ, Sorenmo KU. Assessment of cyclooxygenase-2 expression in canine hemangiosarcoma, histiocytic sarcoma, and mast cell tumor. Vet Pathol 2005, 42(3):350-353. 10.1354/vp.42-3-350, 15872381.
63. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000, 100(1):57-70. 10.1016/S0092-8674(00)81683-9, 10647931.
64. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986, 315(26):1650-1659. 10.1056/NEJM198612253152606, 3537791.
65. D'Alessio S, Blasi F. The urokinase receptor as an entertainer of signal transduction. Front Biosci 2009, 14:4575-4587. 10.2741/3550, 19273372.
66. Allen DL, Teitelbaum DH, Kurachi K. Growth factor stimulation of matrix metalloproteinase expression and myoblast migration and invasion in vitro. Am J Physiol Cell Physiol 2003, 284(4):C805-815.
67. Pusztaszeri MP, Seelentag W, Bosman FT. Immunohistochemical expression of endothelial markers CD31, CD34, von Willebrand factor, and Fli-1 in normal human tissues. J Histochem Cytochem 2006, 54(4):385-395. 10.1369/jhc.4A6514.2005, 16234507.
68. Ishimoto T, Oshima H, Oshima M, Kai K, Torii R, Masuko T, Baba H, Saya H, Nagano O. CD44(+) slow-cycling tumor cell expansion is triggered by cooperative actions of Wnt and prostaglandin E(2) in gastric tumorigenesis. Cancer Sci 2009,
69. Thorsteinsdottir U, Sauvageau G, Hough MR, Dragowska W, Lansdorp PM, Lawrence HJ, Largman C, Humphries RK. Overexpression of HOXA10 in murine hematopoietic cells perturbs both myeloid and lymphoid differentiation and leads to acute myeloid leukemia. Mol Cell Biol 1997, 17(1):495-505. 231774, 8972230.
70. Streubel B, Chott A, Huber D, Exner M, Jager U, Wagner O, Schwarzinger I. Lymphoma-specific genetic aberrations in microvascular endothelial cells in B-cell lymphomas. N Engl J Med 2004, 351(3):250-259. 10.1056/NEJMoa033153, 15254283.
71. Fang B, Zheng C, Liao L, Han Q, Sun Z, Jiang X, Zhao RC. Identification of human chronic myelogenous leukemia progenitor cells with hemangioblastic characteristics. Blood 2005, 105(7):2733-2740. 10.1182/blood-2004-07-2514, 15591120.